Parkinson's Disease - Roche BN44715

Parkinson’s Disease – Roche BN44715

Profound Research is enrolling a Parkinson’s disease study that is assessing an investigational medication to see if it improves motor function.

This can consist of tremors, stiffness or rigidity, slowness of movement, and posture instability.

To be eligible to participate, you must:

Be ages 50-85 with a body weight of 88-242 pounds and a BMI of 18-34
Be diagnosed with Parkinson’s disease for at least 3 months to a maximum of 3 years with slowness of movement [bradykinesia] plus one other symptom
Be taking up to 450 mg of levodopa (Inbrija, Dopar, Larodopa, Crexont, or Rytary) per day
Not have a history of Parkinson’s-related freezing or falling
Not have a diagnosis of Parkinson’s dementia, Huntington’s disease, stroke, Alzheimer’s disease, Multiple Sclerosis, or brain tumor

Qualified participants will receive:

Take action and see if you qualify for a Parkinson’s Disease study.

Trial Interest Form

I am a...

First Name(Required)

Last Name(Required)

Location(Required)

Phone(Required)

Email(Required)

Gender

Conditions

Race

Contact Preference

How did you hear about us?

Other (Please specify)

This field is hidden when viewing the form

Trial (Origination Page)

This field is hidden when viewing the form

UTM Source

This field is hidden when viewing the form

UTM Medium

This field is hidden when viewing the form

UTM Campaign

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

Phone(Required)

Zip Code(Required)

What is the best way to contact you?(Required)

Comments(Required)

Please let us know what's on your mind. Have a question for us? Ask away.

This field is hidden when viewing the form

Origination Page

Parkinson’s Disease – Roche BN44715